Vivesto Stock

Vivesto FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Vivesto (VIVE.ST) as of Aug 10, 2026 is 53.91 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 22.09 % — a change of 144.02% (higher).

FCF Conversion

53.91 %

YoY

144.02%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Vivesto is 2026 53.91 % . FCF Conversion Rate (FCF/EBITDA) of Vivesto was 2025 22.09 % . It decreases by 144.02% higher compared to the previous year.
Access this data via the Eulerpool API

Vivesto Stock analysis

What does Vivesto do? Oasmia Pharmaceutical AB is a Swedish pharmaceutical company that specializes in the development and marketing of innovative cancer and pain medications. The company was founded in 1998 and is headquartered in Uppsala, Sweden. Vivesto is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vivesto stock

FCF Conversion Rate (FCF/EBITDA) of Vivesto is 53.91 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Vivesto changed from 22.09 % to 53.91 %, representing a 144.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Vivesto since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Vivesto with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Vivesto

All Key Metrics — Vivesto